This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

17 Jan 2016

Datatrak's technology driven drug development (TD3) supports clinical trial industry transformation

Patient-focused models, improving adherence, and controlling costs all benefit from TD3.

Datatrak International has announced that more than 100 CROs, 10 of the top 15 pharmaceutical organizations, and 3 top 10 biotechs, are using the DATATRAK ONE UX platform in their efforts to harness technology to drive drug development.

"Technology Driven Drug Development, TD3, is the concept that underlies all technology in Datatrak's product solution portfolio. All of our customers look for every technological edge they can build into their processes. Maximizing the contribution of human and technological resources and consistently improving cost effectiveness is their daily routine. We're delighted that so many organizations are using the power of our DATATRAK ONE UX Platform to enable their success," said Laurence P. Birch, Datatrak CEO. He continued, "We're looking forward to helping the industry drive even greater efficiencies from patient-focused models, capturing big data, and using the resulting insight to increase the speed and efficacy of drug development."

Tim Lyons, Datatrak's Vice President of Product Development and Operations, stated that, "Our strategic investments in technology are moving the bar to help clinical operations capitalize on the viability of their drug pipelines. The DATATRAK ONE UX platform's capability to improve and easily configure workflows can make a huge difference as companies work to mitigate risk via adaptive trial design and risk based monitoring."

Related News